| EPA0101 | UV-C radiation induces disulphide bond cleavage in SARS-CoV-2 spike protein reducing its binding to ACE2 on host cells | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0102 | Persistent immune alterations in individuals with Long-COVID during a 6-months period | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0103 | Humoral immune responses to ancestral SARS-CoV-2 wild type and variant strains following COVID-19 vaccination in people with HIV | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0104 | Comparable cellular response between people living with HIV and healthy donors against SARS-CoV-2 six months after receiving two doses of currently approved COVID-19 vaccines | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0105 | High levels of soluble endothelial cell protein C receptor in plasma of individuals with Long-COVID proves the role of endothelial dysfunction in the persistence of COVID-19 | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0106 | Characterization of SARS-CoV-2 diagnostic and subgenomic RNA viral dynamics and seroconversion via Bayesian hierarchical modeling | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0107 | SARS-CoV-2 infection and Spike protein exposure alter iPSC-derived human brain organoid homeostasis | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| OAA0105 | Are moto-neurons susceptible to SARS-CoV-2 infection? | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| OAA0405 | Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in mice | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| TUPEA12 | Pre-existing immunity restricts plasma and mucosal antibody responses during SARS-CoV-2 Omicron breakthrough infection | Poster exhibition | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |